Santarus, Inc. (NASDAQ:SNTS)

CAPS Rating: 5 out of 5

A pharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by gastroenterologists or primary care physicians.

Results 1 - 20 of 24 : 1 2 Next »

Recs

0
Member Avatar Sherefoy (40.66) Submitted: 12/8/2013 11:39:27 PM : Outperform Start Price: $31.97 SNTS Score: -2.74

Proprietary products

Recs

0
Member Avatar Snaake (< 20) Submitted: 9/26/2013 12:27:42 PM : Outperform Start Price: $22.93 SNTS Score: +29.45

Santarus has five marketable products and is being proactive in acquiring and developing new products before a potential revenue gap in 2016 due to the patent expiration of two of their products. For now, the company is looking at their new drug UCERIS, launched in February 2013, to produce near-term revenue gains. Last quarter, UCERIS added $16.2 million in revenue as compared to $6 million in the previous quarter. Look for increases in sales revenue from UCERIS to keep on going well into 2014. UCERIS was launched in mid-February 2013 and is a non-systemic steroid that controls flares of Ulcerative Colitis without the long-term effects steroids. The reduced side-effects are a selling point to physicians and the company is aggressively marketing UCERIS in a unique sales strategy. Santarus’ sales representatives market all products in small and overlapping territories. For example, two reps might make a call on the same physician but a week or two apart leaving the physician feeling less bothered by the company. Total revenues should increase going forward due to the company’s ability to effectively market UCERIS. But long-term, I will be looking at Santarus’ ability to increase free cash flow as this will allow them to be even more proactive in acquiring and developing new products. A strong pipeline and cash to acquire products or other pharmaceutical companies will be paramount for Santarus’ success but the other key driving force will be its CEO Gerald Proehl, who on July 17 was honored as San Diego Ernst & Young Entrepreneur of the year 2013 in life sciences.

Recs

0
Member Avatar zackf89 (< 20) Submitted: 8/9/2013 10:28:35 AM : Outperform Start Price: $26.73 SNTS Score: +9.67

biotech earnings machine

Recs

1
Member Avatar WilliamCrook2003 (71.47) Submitted: 8/6/2013 3:25:50 PM : Outperform Start Price: $24.84 SNTS Score: +18.90

MF Stock of the Day

Recs

1
Member Avatar eat251heart (51.75) Submitted: 5/29/2013 10:31:55 AM : Outperform Start Price: $22.44 SNTS Score: +29.53

With all the GMO foods and allergies, the American public is going to need help.

Recs

0
Member Avatar Idiot2fool (< 20) Submitted: 5/22/2013 2:48:11 PM : Outperform Start Price: $22.30 SNTS Score: +31.18

may be to late for the rally but oh well.

Recs

0
Member Avatar mchedester (68.35) Submitted: 3/26/2013 5:22:32 AM : Outperform Start Price: $17.66 SNTS Score: +61.18

Forward eps hasn't caught up to growth rate. The only reason this isn't much higher is because it has already gone up so much in the past months. Luckily the market doesn't let anything go straight up and this is where some profit can be made.

Recs

0
Member Avatar markmark69 (< 20) Submitted: 2/27/2013 1:51:16 PM : Outperform Start Price: $13.27 SNTS Score: +117.88

I've owned over 1k shares of SNTS for almost 3yrs. Has several promsing Phase III products in its pipeline. Often overlooked are its cash agreements with Merck and GSK.

Recs

0
Member Avatar vaderblue (59.99) Submitted: 2/11/2013 5:22:26 PM : Outperform Start Price: $13.20 SNTS Score: +119.32

big demand for their products. sales 600+ billion. up to management proficiently

Recs

0
Member Avatar Stan1955 (60.06) Submitted: 1/16/2013 12:33:40 PM : Outperform Start Price: $12.43 SNTS Score: +130.16

Colitis is a very common problem and there will be a huge demand for this drug world wide. Insurance companies will pay big bucks to get the person off their sick beds and back to work.

Recs

0
Member Avatar dunloggin (76.86) Submitted: 10/18/2010 11:11:16 AM : Outperform Start Price: $3.12 SNTS Score: +866.27

Taking a flier on this one.

Recs

0
Member Avatar 21popsontop (< 20) Submitted: 10/14/2010 1:31:12 AM : Outperform Start Price: $3.10 SNTS Score: +872.76

This longshot looks like a warrior on a bear hunt.

Recs

1
Member Avatar humbledutch (60.76) Submitted: 8/19/2010 3:44:40 PM : Outperform Start Price: $2.36 SNTS Score: +1,181.64

Good earnings, strong balance and generating cashflow

Recs

1
Member Avatar therock050383 (< 20) Submitted: 5/20/2010 12:42:24 PM : Outperform Start Price: $2.91 SNTS Score: +926.53

At this point, everyone is assuming the worst case scenario with generic Zegerid regarding Par Pharma, and this is priced into the stock....The company has over $1.50/share in cash alone....At current prices, the rest of the company flagship without the cash is priced at $72 million.....They will have $50 million in Glumetza sales this year, Merck just launched Zegerid OTC 1 1/2 months ago (in which SNTS will receive royalties moving forward), plus two late stage III drugs.....(All priced at $72 million), and they will still have $100 + million in Zegerid prescription sales this year........seems cheap.

Recs

0
Member Avatar graniteguys (64.36) Submitted: 5/19/2010 8:25:42 PM : Outperform Start Price: $2.96 SNTS Score: +909.32

call this a winner easily double

Recs

0
Member Avatar markymark69 (< 20) Submitted: 3/13/2010 3:55:44 AM : Outperform Start Price: $4.68 SNTS Score: +521.19

Great cash flow. Almost no debt. Double digit royalties coming in this year in addition to potential cash payment $35mil from Merck. I'm riding this one out to $7/share

Recs

0
Member Avatar Brian7992 (54.75) Submitted: 8/11/2009 2:29:09 PM : Outperform Start Price: $3.12 SNTS Score: +836.96

Buy me now!

Recs

3
Member Avatar poppinkid (82.02) Submitted: 5/8/2008 9:12:28 PM : Outperform Start Price: $2.51 SNTS Score: +1,133.64

Highly underrated. GERD treatments are not that effective and LR PPI drugs don't provide immediate relief. Zegrid has a IR formulation that is significantly better than current prescriptions and OTC products. Hence, Schering and Glaxo's interest in co-promotion. This is a 14B market, and 5% of that market will make this an easy 4 bagger. The PAR case is causing hang over, but look for that to resolved and for profitability in 2009.

Recs

1
Member Avatar RRUI (< 20) Submitted: 3/5/2008 2:58:35 PM : Outperform Start Price: $2.09 SNTS Score: +1,383.30

SNTS has been hampered primarily by a patent challenge by Par Pharm. and the stock took a huge hit when this claim came out primarily for two reasons. 1) CEO had stopped giving guidance on a call a few days before and 2) market thought that perhaps the patent challenge would further hamper the cash flow situation at SNTS. Realistically, this suit will probably be settled or won by SNTS. SNTS should reach profitability in Q4, however, the market is overlooking the two major deals SNTS has signed with Glaxo (for foreign distribution) and Schering for OTC distribution. Both companies are comfortable with the patents as should you be. I look for a volatile rocky ride from here...but up it should be. Cheers.

Recs

0
Member Avatar meghanjack (94.73) Submitted: 6/29/2007 10:37:57 AM : Outperform Start Price: $5.56 SNTS Score: +445.06

good drug

Results 1 - 20 of 24 : 1 2 Next »

Featured Broker Partners


Advertisement